Matinas BioPharma to Merge with GH Power in Clean Energy Pivot

Matinas BioPharma announced a strategic business combination with GH Power that will transform the pharmaceutical company into a publicly traded advanced clean energy enterprise, marking a dramatic departure from its drug-development roots. The newly formed company will concentrate on modular carbon-free energy, green hydrogen production, critical materials, and industrial decarbonization — sectors that have attracted surging investor and policy attention in recent years.

Simultaneously, Matinas signed a definitive agreement to sell its lipid nanocrystal, or LNC, platform technology and lead product candidate MAT2203 to Azurity Pharmaceuticals. The dual-track move effectively draws a clean line between the company's biotech past and its clean-energy future, allowing both assets to be developed by entities better suited to each respective industry.

Read more Japan's Top Card Network Partners With Circle on Stablecoin Payments →

The GH Power combination positions the resulting company squarely inside the rapidly expanding green hydrogen market, which analysts and policymakers increasingly view as essential to decarbonizing heavy industry, shipping, and power generation. A modular energy focus also suggests the new entity could pursue distributed infrastructure opportunities rather than relying solely on large centralized projects.

For Matinas shareholders, the transaction represents a significant strategic bet: exiting a competitive biopharmaceutical landscape in favor of a capital-intensive but potentially high-growth clean energy space. The sale of MAT2203 and the LNC platform to Azurity ensures that the drug candidate, which had been a centerpiece of Matinas's pipeline, will continue its development path under specialized pharmaceutical ownership.

The full terms of both deals, including financial details and expected closing timelines, were outlined in filings accompanying the announcement. Continue reading at GlobalNewswire.